RUBIUS THERAPEUTICS INC's ticker is RUBY and the CUSIP is 78116T103. A total of 86 filers reported holding RUBIUS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,069 | -99.9% | 6,108 | +236.7% | 0.00% | – |
| Q3 2022 | $787,000 | -81.1% | 1,814 | -62.9% | 0.00% | – |
| Q2 2022 | $4,165,000 | -98.6% | 4,896 | -91.2% | 0.00% | – |
| Q1 2022 | $307,375,000 | +89.2% | 55,785 | +232.3% | 0.00% | – |
| Q4 2021 | $162,498,000 | +6.9% | 16,787 | +97.5% | 0.00% | – |
| Q3 2021 | $151,944,000 | +242.0% | 8,498 | +366.9% | 0.00% | – |
| Q2 2021 | $44,426,000 | -87.3% | 1,820 | -86.3% | 0.00% | -100.0% |
| Q1 2021 | $350,886,000 | +435.6% | 13,241 | +53.4% | 0.00% | – |
| Q4 2020 | $65,517,000 | +35.6% | 8,632 | -10.5% | 0.00% | – |
| Q3 2020 | $48,326,000 | +210.9% | 9,646 | +271.1% | 0.00% | – |
| Q2 2020 | $15,542,000 | -69.7% | 2,599 | -77.4% | 0.00% | – |
| Q1 2020 | $51,277,000 | +12.5% | 11,523 | +140.3% | 0.00% | – |
| Q4 2019 | $45,562,000 | -6.8% | 4,796 | -23.0% | 0.00% | – |
| Q3 2019 | $48,906,000 | -31.9% | 6,230 | +36.5% | 0.00% | – |
| Q2 2019 | $71,792,000 | -47.0% | 4,564 | -39.0% | 0.00% | – |
| Q1 2019 | $135,478,000 | +21507.3% | 7,485 | +19092.3% | 0.00% | – |
| Q4 2018 | $627,000 | -49.8% | 39 | -25.0% | 0.00% | – |
| Q3 2018 | $1,248,000 | – | 52 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |